Doximity Inc logo

Doximity Inc(DOCS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 68 days
PROFIT SINCE LAST BUY
+27.69% ▲
LAST CLOSE
$33.34
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for DOCS

11/13/2026: DOCS (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Doximity operates a leading digital networking and workflow platform utilized by a vast majority of U.S. physicians. The company's primary business strength lies in its high-margin pharmaceutical marketing solutions and daily utility tools like Doximity Dialer. Its core growth opportunity centers on expanding enterprise health system contracts and deploying new AI-powered clinical productivity assistants. However, key risks include revenue concentration among major pharma advertisers and potential macro-driven marketing budget cuts. The stock suits growth-oriented technology investors willing to monitor enterprise sales execution and pharma spending cycles.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile Doximity features strong software margins and cash generation, its revenue growth has moderated compared to early post-IPO rates.
Momentum investorStrong fit while signal remains positiveMomentum appeal depends on near-term earnings beats and positive technical breakouts in software sentiment.
Value investorMixed fitValuation multiples often price in steady profitability, leaving less margin of safety for strict value buyers.
Dividend investorWeak fitThe company does not pay dividends, focusing instead on internal reinvestment and financial flexibility.
Low-risk investorMixed fitAlthough debt-free and cash-generative, the stock experiences growth-equity price volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock can experience sharp price swings driven by shifts in technology sector sentiment and quarterly earnings reports.
Valuation riskMediumA growth-oriented valuation profile means any deceleration in revenue or billings can trigger multiple compression.
Competition risk (AI and digital health competition)MediumRivals and emerging AI healthcare tools could pressure Doximity's engagement metrics or pricing power.
Business qualityStrongDoximity boasts exceptional gross margins, strong cash flow, and a dominant network effect among U.S. doctors.
Dividend incomeLow / noneIncome-focused investors receive no dividend yield from the stock.
Execution riskMediumSuccessfully expanding AI workflow tools and health system enterprise contracts is essential to meeting growth expectations.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 5.95B USD
Price to earnings Ratio 46.31
1Y Target Price 31.5
Price to earnings Ratio 46.31
1Y Target Price 31.5
Volume (30-day avg) 2.8M shares
Beta 1.29
52 Weeks Range 17.15 - 51.84
Updated Date 11/15/2026
52 Weeks Range 17.15 - 51.84
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.72

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Health Information Services

BUY participation
100.0%
Active BUY / eligible
4 / 4
30-Day BUY Count Change
+2

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 37.26%
Avg. Invested days 47
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
DOCS receives a 4-star rating, supported by strong unit economics, solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
DOCS has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2026 versus FY2025, strong cash generation (FCF margin 49.2%) and solid revenue growth (+13.1%) are partially offset by negative earnings growth (-12.2%), modest insider ownership of 3.62%.

Financial Health Rating

★★★★★
DOCS's financial health is supported by strong liquidity, including working-capital and asset support (WC/assets 70.2%). Operating efficiency is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is DOCS's strongest growth driver at +19.0% FY2026 versus FY2025 (solid, 4 stars). By comparison, revenue growth (+13.1%, solid) is also solid, while earnings growth (-12.2%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 95.9% and approximately 97.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.62% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 8.02%
Vanguard Portfolio Management, LLC 3.58%
Vanguard Capital Management, LLC 3.35%
D. E. Shaw & Co LP 3.32%
Two Sigma Investments LLC 2.60%

Unit Economics (Per $1K Revenue)

★★★★★
DOCS generates approximately $891 of gross profit, $333 of operating income, and $492 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 21.58%

Quantitative Style Profile

★★★★★
DOCS has a high-quality, liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Quality TiltHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Marketing SolutionsDigital advertising and promotional programs sold to pharmaceutical manufacturers and health systems.This is Doximity's primary engine, accounting for the vast majority of its revenue.
Hiring and Telehealth SolutionsSubscription and usage fees from health systems for physician recruitment tools and advanced telehealth workflows.Provides secondary diversification away from pharma advertising into health system operational budgets.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When After Market
Estimate 0.19
Actual 0.19

Profitability

Profit Margin 21.12%
Operating Margin (TTM) 27.12%

Management Effectiveness

Return on Assets (TTM) 9.55%
Return on Equity (TTM) 13.81%

Valuation

Trailing PE 46.31
Forward PE 24.51
Enterprise Value 5.24B
Price to Sales(TTM) 8.99
Enterprise Value 5.24B
Price to Sales(TTM) 8.99
Enterprise Value to Revenue 7.93
Enterprise Value to EBITDA 27.45
Shares Outstanding 127.52M
Shares Floating 123.81M
Shares Outstanding 127.52M
Shares Floating 123.81M
Percent Insiders 3.62
Percent Institutions 95.88

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.